The patent covers core Quell technology that regulates electrical stimulation based on the device orientation. No other wearable pain relief device has position dependent stimulation control technology that allows the device to automatically modulate treatment based on the user's body position. This technology is used in Quell's overnight therapy modes as well for other features.
"We are pleased to have received this latest patent, which describes core Quell technology,” said Shai N. Gozani, M.D., Ph.D., president and CEO of NeuroMetrix. “We are continually working to make Quell smarter and more automated so that our customers can focus less on controlling their device and more on enjoying their lives. This patent further establishes Quell as the innovation leader in this area. NeuroMetrix now has 15 issued U.S. utility patents covering Quell technology."